MissionIR Articles
-
MissionIRNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Financial Results, Corporate Highlights for Q4, FY 2023
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced its financial numbers and operational highlights for the fourth quarter and full year ended Dec.…
-
MissionIRNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Enrolls First Patients in Key Study Assessing Proprietary AIMIGo(TM) System
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has begun enrolling the first patients in its VALID-ECG pivotal study. According to the announcement, the first…
-
MissionIRNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Awarded Two New US Patents Covering Core Cardiac Monitoring Technology
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has received notification that two of its patents covering core vectorelectrocardiography (“VECG”) have been awarded by the…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q4 and FY 2023 Results Call
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced that it will hold a conference call to discuss its results for the fourth quarter…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Combines AI, Proprietary Technology to Deliver Unprecedented Cardiac Insights
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced significant developments for the use of artificial intelligence (“AI”) applied to its proprietary vectorelectrocardiography (“VECG”)…
-
MissionIRNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q3 2023 Financial Report, Operational Update
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for artificial intelligence…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Expands Scientific Advisory Board as It Advances Product Development, Clinical and Commercial Efforts
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, today announced the expansion of its scientific advisory board (“SAB”)…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Third Quarter 2023 Results Conference Call
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, announced that it will hold a conference call on Tuesday,…
-
MissionIRNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Experienced Leaders to New Senior Management Positions
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home allowing for the creation of rich data for AI, has…
-
MissionIRNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q2 2023 Financial Report, Corporate Update
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, is reporting its financial and operational results for the second…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces First Peer-Reviewed Publication Based on Its VECG Technology
HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for AI.…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Appoints Deborah Castillo to Lead Regulatory Strategy and Execution
HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for AI.…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q2 2023 Results Call, Webcast
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced that it will hold a conference call to discuss…
-
MissionIRNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Experienced Physician, Researcher to Board of Directors
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, has announced a new member of its board of directors:…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Adds Wealth of Expertise to Its Board with Appointments of Ken Nelson and Mark Strome
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced the appointment of Ken Nelson and Mark Strome to…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Enters SAA with Samsung
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced its entry into a strategic alliance agreement (“SAA”)…
-
MissionIRNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Granted Key Patent for Use in Innovative System Designed to Help Evaluate Cardiac Symptoms
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, has been granted a patent for the automated cardiac detection…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces FDA 510(k) Submission of HeartBeam AIMIGo(TM) Solution
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced it has submitted a 510(k) application to the…
-
MissionIRNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q1 2023 Financial Report, Corporate Updates
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is reporting its operational and financial results for the first quarter…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Completes $25M Capital Raise to Achieve Upcoming Milestones, Extend Cash Runway
HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform to help physicians detect heart attacks anytime, anywhere as well as diagnose other common heart conditions.…
Search Articles
Latest Articles
- VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline
- MissionIRNewsBreaks – Greenland Energy Company (NASDAQ: GLND) Advances Jameson Land Basin Toward Exploration Drilling
- MissionIRNewsBreaks – Massimo Group (NASDAQ: MAMO) Terminates Proposed FST Acquisition, Refocuses on Internal Security Technology Development
- MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
- Beeline Holdings Inc. (NASDAQ: BLNE) Joins Russell Microcap Index as Digital Mortgage Platform Expands AI and Equity Strategy